United Therapeutics Chairperson & CEO Martine A. Rothblatt Sells $5.18M of Stock
Martine A. Rothblatt, Chairperson & CEO, sold 9,500 shares of United Therapeutics Corp at $542.76 to $551.49 a share (average $545.52) in 10 transactions, worth $5.18M in total on Oct 13, 2026. Shares held after the trade: 324,443 (-0.0%).
United Therapeutics entered into a comprehensive settlement agreement with Liquidia Technologies to resolve multiple patent infringement and trade secret lawsuits. Liquidia will pay United Therapeutics $330.4 million in damages and has agreed to remove the PH-ILD indication from its Yutrepia product labeling, while United Therapeutics will pay Liquidia $10.0 million to resolve separate infringement claims.
United Therapeutics Chairperson & CEO Martine A. Rothblatt Sells $5.23M of Stock
Martine A. Rothblatt, Chairperson & CEO, sold 9,500 shares of United Therapeutics Corp at $548.13 to $554.46 a share (average $550.70) in 7 transactions, worth $5.23M in total on Oct 12, 2026. Shares held after the trade: 324,443 (-0.0%).
United Therapeutics Chairperson & CEO Martine A. Rothblatt Sells $5.18M of Stock
Martine A. Rothblatt, Chairperson & CEO, sold 9,500 shares of United Therapeutics Corp at $531.92 to $550.72 a share (average $544.94) in 17 transactions, worth $5.18M in total on Oct 9, 2026. Shares held after the trade: 324,443 (-0.1%).
United Therapeutics Chairperson & CEO Martine A. Rothblatt Sells $5.08M of Stock
Martine A. Rothblatt, Chairperson & CEO, sold 9,500 shares of United Therapeutics Corp at $525.50 to $541.23 a share (average $534.31) in 16 transactions, worth $5.08M in total on Oct 8, 2026. Shares held after the trade: 324,443 (-0.0%).
United Therapeutics Chairperson & CEO Martine A. Rothblatt Sells $5.22M of Stock
Martine A. Rothblatt, Chairperson & CEO, sold 9,500 shares of United Therapeutics Corp at $542.73 to $556.48 a share (average $548.95) in 14 transactions, worth $5.22M in total on Oct 7, 2026. Shares held after the trade: 326,883 (-0.1%).
United Therapeutics Chairperson & CEO Martine A. Rothblatt Sells $5.12M of Stock
Martine A. Rothblatt, Chairperson & CEO, sold 9,500 shares of United Therapeutics Corp at $527.90 to $545.50 a share (average $538.67) in 17 transactions, worth $5.12M in total on Oct 6, 2026. Shares held after the trade: 331,171 (-0.0%).
United Therapeutics Chairperson & CEO Martine A. Rothblatt Sells $5.15M of Stock
Martine A. Rothblatt, Chairperson & CEO, sold 9,500 shares of United Therapeutics Corp at $536.26 to $546.63 a share (average $541.64) in 11 transactions, worth $5.15M in total on Oct 5, 2026. Shares held after the trade: 325,723 (-0.4%).
United Therapeutics Chairperson & CEO Martine A. Rothblatt Sells $5.22M of Stock
Martine A. Rothblatt, Chairperson & CEO, sold 9,500 shares of United Therapeutics Corp at $542.06 to $574.23 a share (average $549.37) in 23 transactions, worth $5.22M in total on Oct 2, 2026. Shares held after the trade: 326,648 (-0.1%).
United Therapeutics Chairperson & CEO Martine A. Rothblatt Sells $5.48M of Stock
Martine A. Rothblatt, Chairperson & CEO, sold 9,500 shares of United Therapeutics Corp at $560.05 to $584.66 a share (average $576.47) in 19 transactions, worth $5.48M in total on Oct 1, 2026. Shares held after the trade: 331,489 (-0.1%).
United Therapeutics EVP & General Counsel Paul A. Mahon Sells $4.69M of Stock
Paul A. Mahon, EVP & General Counsel, sold 8,300 shares of United Therapeutics Corp at $558.30 to $573.15 a share (average $564.95) in 10 transactions, worth $4.69M in total on Oct 1, 2026. Shares held after the trade: 45,332 (-1.8%).
United Therapeutics Chairperson & CEO Martine A. Rothblatt Sells $1.06M of Stock
Martine A. Rothblatt, Chairperson & CEO, sold 1,920 shares of United Therapeutics Corp at $547.29 to $554.70 a share (average $550.22) in 8 transactions, worth $1.06M in total on Sep 30, 2026. Shares held after the trade: 324,443 (-0.1%).
United Therapeutics Chairperson & CEO Martine A. Rothblatt Sells $3.93M of Stock
Martine A. Rothblatt, Chairperson & CEO, sold 7,580 shares of United Therapeutics Corp at $476.14 to $546.23 a share (average $517.97) in 24 transactions, worth $3.93M in total on Sep 30, 2026. Shares held after the trade: 331,103 (-0.0%).
United Therapeutics Chairperson & CEO Martine A. Rothblatt Sells $4.54M of Stock
Martine A. Rothblatt, Chairperson & CEO, sold 9,500 shares of United Therapeutics Corp at $472.05 to $486.77 a share (average $477.42) in 12 transactions, worth $4.54M in total on Sep 29, 2026. Shares held after the trade: 325,263 (-0.0%).
United Therapeutics Chairperson & CEO Martine A. Rothblatt Sells $4.7M of Stock
Martine A. Rothblatt, Chairperson & CEO, sold 9,500 shares of United Therapeutics Corp at $492.91 to $498.25 a share (average $494.79) in 6 transactions, worth $4.7M in total on Sep 18, 2026. Shares held after the trade: 324,443 (-0.0%).
United Therapeutics EVP & General Counsel Paul A. Mahon Sells $4.13M of Stock
Paul A. Mahon, EVP & General Counsel, sold 8,300 shares of United Therapeutics Corp at $495.97 to $501.58 a share (average $497.54) in 7 transactions, worth $4.13M in total on Sep 17, 2026. Shares held after the trade: 45,172 (-0.7%).
United Therapeutics Chairperson & CEO Martine A. Rothblatt Sells $4.71M of Stock
Martine A. Rothblatt, Chairperson & CEO, sold 9,500 shares of United Therapeutics Corp at $493.22 to $501.60 a share (average $496.06) in 9 transactions, worth $4.71M in total on Sep 17, 2026. Shares held after the trade: 324,443 (-0.0%).